FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179885110> ?p ?o ?g. }

• W3179885110 endingPage "e1257" @default.
• W3179885110 startingPage "e1246" @default.
• W3179885110 abstract "PURPOSE: Patient-reported outcomes may be associated with cancer outcomes. We evaluated clinically significant fatigue (CSF), overall survival, adverse events (AEs), and quality of life (QOL) during cancer treatment. METHODS: We compared outcomes in four phase II or III chemotherapy trials, two advanced non–small-cell lung cancer and two advanced hormone-refractory prostate cancer, with or without baseline CSF. CSF was defined as a rating of two or greater on the Functional Assessment of Cancer Therapy fatigue question or a European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 fatigue symptom score of 50% or greater. Survival was compared according to CSF using Kaplan-Meier estimates and Cox regression models. Differences in AE rates by CSF were assessed via chi-squared tests, and QOL changes from baseline to 3 months via linear regression. RESULTS: Of 1,994 participants, 1,907 (median age 69 years, range: 32-91) had complete baseline QOL survey data, with 52% reporting CSF at baseline. For the two hormone-refractory prostate cancer studies, baseline CSF was associated with higher mortality rates, with adjusted hazard ratios of (95% CI, P value) 1.32 (1.13 to 1.55, P < .001) and 1.31 (1.02 to 1.67, P = .03) and with increased incidence of grade 3-5 constitutional (16.5% v 9.4%, P = .002; 13.9% v 6.3%, P = .002) and neurologic (11.7% v 6.1%, P = .006; 9.0% v 3.9%, P = .01) AEs, respectively. Baseline CSF was associated with a higher mortality rate in one non–small-cell lung cancer study: hazard ratio 1.44 and 1.04 to 2.00, P = .03. CONCLUSION: Oncology trial participants with baseline CSF had poorer survival and experienced more AEs than participants without CSF. This indicates fatigue as an important baseline prognostic factor in oncology treatment trials." @default.
• W3179885110 created "2021-07-19" @default.
• W3179885110 creator A5025528921 @default.
• W3179885110 creator A5037211206 @default.
• W3179885110 creator A5042564531 @default.
• W3179885110 creator A5047392346 @default.
• W3179885110 creator A5048654505 @default.
• W3179885110 creator A5072257104 @default.
• W3179885110 creator A5075448643 @default.
• W3179885110 creator A5091192260 @default.
• W3179885110 creator A5091772334 @default.
• W3179885110 date "2021-08-01" @default.
• W3179885110 modified "2023-09-30" @default.
• W3179885110 title "Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials" @default.
• W3179885110 cites W1481970999 @default.
• W3179885110 cites W1545484310 @default.
• W3179885110 cites W1858949386 @default.
• W3179885110 cites W1935885922 @default.
• W3179885110 cites W1940235639 @default.
• W3179885110 cites W1993262172 @default.
• W3179885110 cites W1997253444 @default.
• W3179885110 cites W2002330540 @default.
• W3179885110 cites W2026548146 @default.
• W3179885110 cites W2036751037 @default.
• W3179885110 cites W2051814620 @default.
• W3179885110 cites W2055281658 @default.
• W3179885110 cites W2059616989 @default.
• W3179885110 cites W2067344172 @default.
• W3179885110 cites W2080439368 @default.
• W3179885110 cites W2085791773 @default.
• W3179885110 cites W2088280058 @default.
• W3179885110 cites W2090358445 @default.
• W3179885110 cites W2105258029 @default.
• W3179885110 cites W2113046540 @default.
• W3179885110 cites W2115083140 @default.
• W3179885110 cites W2119968490 @default.
• W3179885110 cites W2120940824 @default.
• W3179885110 cites W2121828573 @default.
• W3179885110 cites W2150471053 @default.
• W3179885110 cites W2153272286 @default.
• W3179885110 cites W2155877563 @default.
• W3179885110 cites W2158119930 @default.
• W3179885110 cites W2158877923 @default.
• W3179885110 cites W2165759229 @default.
• W3179885110 cites W2177704039 @default.
• W3179885110 cites W2182890600 @default.
• W3179885110 cites W2341775483 @default.
• W3179885110 cites W2806271234 @default.
• W3179885110 cites W281780641 @default.
• W3179885110 cites W2990422537 @default.
• W3179885110 cites W3024779615 @default.
• W3179885110 cites W4250790088 @default.
• W3179885110 doi "https://doi.org/10.1200/op.20.01096" @default.
• W3179885110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8360454" @default.
• W3179885110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34255538" @default.
• W3179885110 hasPublicationYear "2021" @default.
• W3179885110 type Work @default.
• W3179885110 sameAs 3179885110 @default.
• W3179885110 citedByCount "5" @default.
• W3179885110 countsByYear W31798851102022 @default.
• W3179885110 countsByYear W31798851102023 @default.
• W3179885110 crossrefType "journal-article" @default.
• W3179885110 hasAuthorship W3179885110A5025528921 @default.
• W3179885110 hasAuthorship W3179885110A5037211206 @default.
• W3179885110 hasAuthorship W3179885110A5042564531 @default.
• W3179885110 hasAuthorship W3179885110A5047392346 @default.
• W3179885110 hasAuthorship W3179885110A5048654505 @default.
• W3179885110 hasAuthorship W3179885110A5072257104 @default.
• W3179885110 hasAuthorship W3179885110A5075448643 @default.
• W3179885110 hasAuthorship W3179885110A5091192260 @default.
• W3179885110 hasAuthorship W3179885110A5091772334 @default.
• W3179885110 hasBestOaLocation W31798851102 @default.
• W3179885110 hasConcept C121608353 @default.
• W3179885110 hasConcept C126322002 @default.
• W3179885110 hasConcept C143998085 @default.
• W3179885110 hasConcept C159110408 @default.
• W3179885110 hasConcept C197934379 @default.
• W3179885110 hasConcept C207103383 @default.
• W3179885110 hasConcept C2776256026 @default.
• W3179885110 hasConcept C2779951463 @default.
• W3179885110 hasConcept C2780192828 @default.
• W3179885110 hasConcept C44249647 @default.
• W3179885110 hasConcept C50382708 @default.
• W3179885110 hasConcept C71924100 @default.
• W3179885110 hasConceptScore W3179885110C121608353 @default.
• W3179885110 hasConceptScore W3179885110C126322002 @default.
• W3179885110 hasConceptScore W3179885110C143998085 @default.
• W3179885110 hasConceptScore W3179885110C159110408 @default.
• W3179885110 hasConceptScore W3179885110C197934379 @default.
• W3179885110 hasConceptScore W3179885110C207103383 @default.
• W3179885110 hasConceptScore W3179885110C2776256026 @default.
• W3179885110 hasConceptScore W3179885110C2779951463 @default.
• W3179885110 hasConceptScore W3179885110C2780192828 @default.
• W3179885110 hasConceptScore W3179885110C44249647 @default.
• W3179885110 hasConceptScore W3179885110C50382708 @default.
• W3179885110 hasConceptScore W3179885110C71924100 @default.
• W3179885110 hasIssue "8" @default.
• W3179885110 hasLocation W31798851101 @default.

• next